Comparative Pharmacology
Head-to-head clinical analysis: DESOGESTREL AND ETHINYL ESTRADIOL versus FEMTRACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESOGESTREL AND ETHINYL ESTRADIOL versus FEMTRACE.
DESOGESTREL AND ETHINYL ESTRADIOL vs FEMTRACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desogestrel is a progestin that suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary axis, further suppressing ovulation and altering cervical mucus and endometrial lining to reduce sperm penetration and implantation.
Estrogen receptor agonist; binds to estrogen receptors, modulating gene transcription and cellular proliferation in target tissues.
One tablet (0.15 mg desogestrel/0.03 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo tablets, then repeat cycle.
1 to 2 mg orally once daily; for testosterone replacement in adult males, 2 to 4 mg orally once daily.
None Documented
None Documented
Desogestrel: terminal half-life 23-27 hours (active metabolite etonogestrel); clinically allows once-daily dosing. Ethinyl estradiol: terminal half-life 12-15 hours (range 10-20 hours) with biphasic elimination; supports daily administration.
Terminal elimination half-life is approximately 12-14 hours, supporting once-daily dosing in clinical use.
Desogestrel: primarily renal (approximately 60% as metabolites), 30% fecal. Ethinyl estradiol: primarily renal (approximately 40% as glucuronide conjugates), 60% fecal.
Primarily renal; ~40% as unchanged drug and glucuronide conjugates. Biliary/fecal elimination is minor (~10-15%).
Category D/X
Category C
Estrogen
Estrogen